Driving force from authorities: the evolution of innovation system for biomedical industry in China

References

• Asakawa, K., and M. Lehrer. 2004. “Rethinking the Public Sector: Idiosyncrasies of Biotechnology Commercialization as Motors of National R&D Reform in Germany and Japan.” Research Policy 33: 921–938. doi: 10.1016/j.respol.2004.01.011
   Web of Science ®Google Scholar
• Campbell, D., and M. Chui. 2010. Pharmerging Shake-Up. Norwalk: IMS Health.
   Google Scholar
• Casper, S., and C. Matraves. 2003. “Institutional Frameworks and Innovation in the German and UK Pharmaceutical Industry.” Research Policy 32: 1865–1879. doi: 10.1016/S0048-7333(03)00082-9
   Web of Science ®Google Scholar
• Chakma, J., S. M. Sammut, and A. Agrawal. 2013. “Life Sciences Venture Capital in Emerging Markets.” Nature Biotechnology 31: 195–201. doi: 10.1038/nbt.2529
   PubMed Web of Science ®Google Scholar
• Chakma, J., G. H. Sun, J. D. Steinberg, S. M. Sammut, and R. Jagsi. 2014. “Asia’s Ascent – Global Trends in Biomedical R&D Expenditures.” New England Journal of Medicine 370: 3–6. doi: 10.1056/NEJMp1311068
   PubMed Web of Science ®Google Scholar
• Chakraborty, C., and G. Agoramoorthy. 2010. “A Special Report on India’s Biotech Scenario: Advancement in Biopharmaceutical and Health Care Sectors.” Biotechnology Advances 28: 1–6. doi: 10.1016/j.biotechadv.2009.10.007
   PubMed Web of Science ®Google Scholar
• Chung, C. C. 2013. “Government, Policy-Making and the Development of Innovation System: The Cases of Taiwanese Pharmaceutical Biotechnology Policies (2000–2008).” Research Policy 42: 1053–1071. doi: 10.1016/j.respol.2013.01.007
   Web of Science ®Google Scholar
• Cloete, T. E., L. H. Nel, and J. Theron. 2006. “Biotechnology in South Africa.” Trends in Biotechnology 24: 557–562. doi: 10.1016/j.tibtech.2006.10.009
   PubMed Web of Science ®Google Scholar
• Conle, M., and M. Taube. 2010. “Regional Specialization in China’s Biopharmaceutical Industry.” Chinese Management Studies 4: 339–359. doi: 10.1108/17506141011094136
   Web of Science ®Google Scholar
• CPEMA. 2009. Development Report on China’s Pharmaceutical Industry (1949–2009). Beijing: Chemical Industry Press, Chinese Pharmaceutical Enterprises Association. pp. 1.
   Google Scholar
• Drabu, S., A. Gupta, and A. Bhadauria. 2010. “Emerging Trends in Contract Research Industry in India.” Contemporary Clinical Trials 31: 419–422. doi: 10.1016/j.cct.2010.06.008
   PubMed Web of Science ®Google Scholar
• Engel, J. S., and I. del-Palacio. 2009. “Global Networks of Clusters of Innovation: Accelerating the Innovation Process.” Business Horizons 52: 493–503. doi: 10.1016/j.bushor.2009.06.001
   Web of Science ®Google Scholar
• Etzkowitz, H. 1993. “Technology Transfer: The Second Academic Revolution.” Technology Access Report 6: 7–9.
   Google Scholar
• Etzkowitz, H., and L. Leydesdorff. 1995. “The Triple Helix – University–Industry–Government Relations: A Laboratory for Knowledge Based Economic Development.” EASST Review 14: 14–19.
   Google Scholar
• Etzkowitz, H., and L. Leydesdorff. 2000. “The Dynamics of Innovation: From National Systems and‘Mode-2’ to a Triple Helix of University–Industry–Government Relations.” Research Policy 29: 109–123. doi: 10.1016/S0048-7333(99)00055-4
   Web of Science ®Google Scholar
• Frew, S. E., H. E. Kettler, and P. A. Singer. 2008. “The Indian and Chinese Health Biotechnology Industries: Potential Champions of Global Health?” Health Affairs 27: 1029–1041. doi: 10.1377/hlthaff.27.4.1029
   Web of Science ®Google Scholar
• Gautam, A., and S. Yang. 2014. “Market Watch: A Framework for Biomedical Innovation in Emerging Markets.” Nature Reviews Drug Discovery 13: 646–647. doi: 10.1038/nrd4413
   PubMed Web of Science ®Google Scholar
• Giesecke, S. 2000. “The Contrasting Roles of Government in the Development of Biotechnology Industry in the US and Germany.” Research Policy 29: 205–223. doi: 10.1016/S0048-7333(99)00061-X
   Web of Science ®Google Scholar
• Hagedoorn, U., and M. Cloodt. 2003. “Measuring Innovative Performance: Is There an Advantage in Using Multiple Indicators?” Research Policy 32: 1365–1379. doi: 10.1016/S0048-7333(02)00137-3
   Web of Science ®Google Scholar
• Hu, M. C., and S. C. Hung. 2014. “Taiwan’s Pharmaceuticals: A Failure of the Sectoral System of Innovation?” Technological Forecasting and Social Change 88: 162–176. doi: 10.1016/j.techfore.2014.06.021
   Web of Science ®Google Scholar
• Kaiser, R., and H. Prange. 2004. “The Reconfiguration of National Innovation Systems—The Example of German Biotechnology.” Research Policy 33: 395–408. doi: 10.1016/j.respol.2003.09.001
   Web of Science ®Google Scholar
• Kato, M., and H. Odagiri. 2012. “Development of University Life-science Programs and University–Industry Joint Research in Japan.” Research Policy 41: 939–952. doi: 10.1016/j.respol.2012.02.011
   Web of Science ®Google Scholar
• Kuah, A. T. H. 2002. “Cluster Theory and Practice: Advantages for the Small Business Locating in a Vibrant Cluster.” Journal of Research in Marketing and Entrepreneurship 4: 206–228. doi: 10.1108/14715200280001472
   Google Scholar
• Lawrence, R. 2005. “New Opportunities in Asia: A Focus on India and China.” Drug Discovery Today 10: 89–91. doi: 10.1016/S1359-6446(04)03315-X
   PubMedGoogle Scholar
• Leydesdorff, L. 2010. “The Knowledge-Based Economy and the Triple Helix Model.” Annual Review of Information Science and Technology 44: 367–417.
   Web of Science ®Google Scholar
• Leydesdorff, L., and H. Etzkowitz. 1998. “The Triple Helix as a Model for Innovation Studies.” Science and Public Policy 25: 195–203.
   Google Scholar
• Leydesdorff, L., and G. Zawdie. 2010. “The Triple Helix Perspective of Innovation Systems.” Technology Analysis and Strategic Management 22: 789–804. doi: 10.1080/09537325.2010.511142
   Web of Science ®Google Scholar
• Lu, Y. 2012. Report on Development of Shanghai Biomedical Industry. Shanghai: Shanghai Science and Technology Press. pp. 89–92.
   Google Scholar
• McMillan, G. S., F. Narin, and D. L. Deeds. 2000. “An Analysis of the Critical Role of Public Science in Innovation: The Case of Biotechnology.” Research Policy 29: 1–8. doi: 10.1016/S0048-7333(99)00030-X
   Web of Science ®Google Scholar
• Moses III, H., D. H. M. Matheson, S. Cairns-Smith, B. P. George, C. Palisch, E. R. Dorsey. 2015. “The Anatomy of Medical Research: US and International Comparisons.” JAMA 313: 174–189. doi: 10.1001/jama.2014.15939
   PubMed Web of Science ®Google Scholar
• MOST (Ministry of Science and Technology of People’s Republic of China). 2009. Report on Biomedical Development Strategy in China—Park. Beijing: Science Press. pp. 115–117.
   Google Scholar
• Muller, C., and T. Fujiwara. 2002. “The Commercialization of Biotechnology in Japan.” Drug Discovery Today 7: 699–704. doi: 10.1016/S1359-6446(02)02232-8
   PubMed Web of Science ®Google Scholar
• NBS, NDRC, MOST. 2009–13. China Statistics Yearbook on High Technology Industry 2009, 2010, 2011, 2012, 2013. Beijing: China Statistics Press.
   Google Scholar
• Pavitt, K. 2001. “Public Policies to Support Basic Research: What Can the Rest of the World Learn from US Theory and Practice? (And What They Should Not Learn).” Industrial and Corporate Change 10: 761–779. doi: 10.1093/icc/10.3.761
   Google Scholar
• Peet, N. P. 2005. “Biotechnology in India.” Drug Discovery Today 10: 1137–1139. doi: 10.1016/S1359-6446(05)03588-9
   PubMed Web of Science ®Google Scholar
• Rezaie, R., A. M. McGahan, E. F. Frew, A. S. Daar, P. A. Singer. 2012. “Emergence of Biopharmaceutical Innovators in China, India, Brazil, and South Africa as Global Competitors and Collaborators.” Health Research Policy and Systems 10: 18–30. doi: 10.1186/1478-4505-10-18
   PubMed Web of Science ®Google Scholar
• Saberwal, G. 2013. “Giving Voice to India’s Entrepreneurs.” Nature Biotechnology 31: 104–107. doi: 10.1038/nbt.2493
   PubMed Web of Science ®Google Scholar
• Shen, X. M. 2014. Choose Pudong, Choose the Future. Speech in Tsinghua University. http://www.jfdaily.com/pl/bw/201412/t20141228_1096188.html.
   Google Scholar
• Simonetti, R., E. Archambault, G. Côté, & D. Kale. 2007. “The Dynamics of Pharmaceutical Patenting in India: Evidence from USPTO Data.” Technology Analysis and Strategic Management 19: 625–642. doi: 10.1080/09537320701521382
   Web of Science ®Google Scholar
• STCSM. 2013. Shanghai Science and Technology Progress Report. http://www.stcsm.gov.cn/newspecial/2013jb/ym1.html.
   Google Scholar
• Su, Y. S., and L. C. Hung. 2009. “Spontaneous vs. Policy-Driven: The Origin and Evolution of the Biotechnology Cluster.” Technological Forecasting and Social Change 76: 608–619. doi: 10.1016/j.techfore.2008.08.008
   Web of Science ®Google Scholar
• Tulum, O., and W. Lazonick. 2011. “US Biopharmaceutical Finance and the Sustainability of the Biotech Business Model.” Research Policy 40: 1170–1187. doi: 10.1016/j.respol.2011.05.021
   Web of Science ®Google Scholar
• Walshe, K., and H. T. Davies. 2013. “Health Research, Development and Innovation in England from 1988 to 2013: From Research Production to Knowledge Mobilization.” Journal of Health Services Research & Policy 18: 1–12. doi: 10.1177/1355819613502011
   PubMed Web of Science ®Google Scholar
• Wang, F. 2012. “The Evolution of Biopharmaceutical Innovation Network—A Case Study on Zhangjiang.” Science Research Management 33: 48–54.
   Google Scholar
• Zhang, F. Z., and F. L. Wu. 2012. “‘Fostering Indigenous Innovation Capacities’: The Development of Biotechnology in Shanghai’s Zhangjiang High-Tech Park.” Urban Geography 33: 728–755. doi: 10.2747/0272-3638.33.5.728
   Web of Science ®Google Scholar